Psoriatic Arthritis Treatment Market is Worth $17.8 Bn By 2026

Psoriatic Arthritis Treatment

A report by ARC estimated that the psoriatic arthritis treatment market will surpass $17.8 billion by 2026, representing an average annual growth rate of 9.9 percent from 2019 to 2026. The report provides analysis of global Psoriatic Arthritis Treatment market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

As fertility in the region has decreased over the years, Europe retained the bulk of the market share in 2018. Pregnancy delays and shifts in lifestyles contribute to this decrease. As a US fertility rate in 2018, North America was the second biggest market. According to the National Center for Health Statistics, only 62,5 children per Psoriatic arthritis is a type of arthritis that occurs in psoriasis patients. It leads to swollen, steep and painful joints. Most individuals with psoriasis were diagnosed with psoriatic arthritis first and later. Around 15-25% of psoriasis individuals may develop psoriatic arthritis. Psoriatic arthritis symptoms include swollen joint, nail pitting, low back pain, conjunctivitis, foot pain.1,000 females were born.

Download Free Sample Report Pages for Better Understanding, Download Here

The development is driven by the emergence of biological similarities, the launching of fresh products and the increasing consciousness by the customer. Among other drug classes in 2018, biologics produced the largest income. The growth segment is driven by demand for targeted therapy, enhanced safety & effectiveness profiles, expected launching of several pipeline applicants as well as powerful commercial performance of current goods. DMARDs will also retain a consistent development rate with the initial action of corticosteroids and the imminent release of JAK and TYK2 kinase inhibitors.

Led by a high level of healthcare expenditures, disease prevalence, the regional presence of important producers, and fast growth in consumer consciousness, in 2018 North America recorded the largest market share. Asia-Pacific is expected to show regional development in the forecast period as quickly as possible, driven by the growing trend of biosimiles, improvements in health infrastructure and higher disposable income.

The therapy of psoriatic arthritis (PSA), owing to biological and biosimilar therapies and the increasing use of new medicines, is continuously gaining great demand. Manufacturers have, in latest years, focused on strategic collaboration for the expansion of their companies in emerging markets and the creation of biological similar products. As a consequence of the introduction of biosimilars that undergo clinical trial programs the worldwide demand for psoriatic arthritis (PsA) therapy is increasing.

The psoriatic arthritis (Psa), which is anticipated to be caused by the growing incidence of psoriatic Arthritis (PsA) throughout the globe and by increased clinical research for the creation of new drugs for the therapy of psoriatic arthritis, is likely to grow steadily during the forecast period. An additional factor in economic growth, which also contribute to the growth of the Psoriatic Arthritis (PsA) industry, is the rise in financing for research and development.

Key Findings

In 2018, biodiversity accounted for over 50% of the market in psoriatic arthritis therapy. Infliximab, Risankizumab, guselkumab, bimekizumab, and tildrakizumab are expected to grow.

The marketplace is expected to increase. The development of DMARDs is probably positive for upadacitinib, filgotinib, and BMS-986 165 — once it is launched.

Injectables represented in 2018 the biggest market share of PsA therapy among other paths.

In 2018, over half its income share was jointly recorded in North America and Europe and important growth is expected to take place in the coming years.

Key Players & Strategies

Some main players include Bristol-Myers Squibb Corporation, AbbVie Inc., Amgen Inc., Bausch Health Companies Inc. ; Johnson & Johnson Services Inc., AstraZenect plc, Celgene Corporation, Novartis International AG, and Pfizer Inc. University of Collaboration, Partnerships and Joint Ventures. Strategic projects, such as fusions and acquisitions, are becoming a heavy-handed market.

The main topics of this competitive landscape are continuous product development and successive launch of breakthrough products. In this industry, fresh products must have a major clinical benefit over current products, either in safety or efficacy, as the regulatory processes become more rigorous and competitive, or as the final outcome. This has resulted in many tests between important business goods, such as Humira and Remicade, and fresh goods or applicants for late-stage pipelines. Through comparative assessment of several parameters, these tests determine superior efficiency.

There is a high level of rivalry between players in the world market for Psoriatic Arthritis Treatments. The market is dominated by technologically sophisticated major players. The industry in Psoriatic Arthritis Treatment is capital-intensive and technological.

Market Segment Analysis:

Acumen Research report focuses on market attractiveness by assessing the key market segments. The report also combines region-wise segments for a better understanding of the supply and demand ratio of the global psoriatic arthritis treatment market. This exclusive study of the report analyzes the present and future market scenario and the industry trends that are influencing the growth of the segments. Besides, the report also covers the value chain analysis, supply chain analysis, and year-on-year basis analysis of the global psoriatic arthritis treatment market.

Market Segmentation

Market, By Drug Class

  • NSAIDs
  • Biologics
  • Others

Market, By Product Type

  • OTC
  • Prescriptions

Market, By Route of Administration

  • Oral
  • Topical
  • Injectable

Market, By Geography

  • North America.
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “Psoriatic Arthritis Treatment Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026” offers detailed insights on global Psoriatic Arthritis Treatment market segments with market dynamics and their impact. The report also covers basic technology development policies.

This report provides an analysis of the latest trends in industries in each segment between 2015 and 2026 and forecasts the growth of income at the global, regional and country levels. ARC segmented the worldwide market in Psoriatic Arthritis Treatment based on drug class, product type, route of administration, and region for this research:

Contact Here, | +1 407 915 4157 OR +1 408 900 9135

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report –

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Leave a Reply

Your email address will not be published. Required fields are marked *

   Contact: +14079154157 | +14089009135 | Email:

Scroll to Top